Cargando…
Expression of COX-1, COX-2, 5-LOX and [Formula: see text] in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
BACKGROUND: Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role...
Autores principales: | Vorsprach, Monique, Arens, Christoph, Knipping, Stephan, Jechorek, Dörte, Stegemann-Koniszewski, Sabine, Lücke, Eva, Schreiber, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933683/ https://www.ncbi.nlm.nih.gov/pubmed/31889962 http://dx.doi.org/10.1186/s13223-019-0395-5 |
Ejemplares similares
-
Thiazoles and Thiazolidinones as COX/LOX Inhibitors
por: Liaras, Konstantinos, et al.
Publicado: (2018) -
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma
por: Harrington, Louise S., et al.
Publicado: (2008) -
Aspirin for the prevention and treatment of pre‐eclampsia: A matter of COX‐1 and/or COX‐2 inhibition?
por: Mirabito Colafella, Katrina M., et al.
Publicado: (2019) -
Inhibition of Angiogenesis In Vitro by Chebulagic Acid: A COX-LOX Dual Inhibitor
por: Athira, A. P., et al.
Publicado: (2013) -
COX-2 and EGFR: Partners in Crime Split by Aspirin
por: Patrignani, Paola, et al.
Publicado: (2015)